JPRN-jRCT2051200062进行中（未招募）2 期
ivolumab for malig nant mesothelioma from non-pleural orig in : A multicenter sing le-arm phase II study - VIOLA Study
Kijima Takashi0 个研究点目标入组 23 人开始时间: 2020年10月5日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 23
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Patients over 20 years old
- •2. Patients diagnosed with malignant mesothelioma (remove the pleura) by histological diagnosis.
- •3. Patients who are determined by the investigator or sub investigator to have at least one measurable lesion as defined in RECIST Version 1.1 by CT or MRI on imaging within 14 days prior to enrollment.However, for malignant mesothelioma other than malignant peritoneal mesothelioma such as pericardium and tunica vaginalis, the presence or absence of measurable lesions does not matter.
- •4. Any history of treatment for malignant mesothelioma (remove the pleura) is warranted. Excluding patients previously treated with drugs specified in the exclusion criteria (15).
- •5. Patients with an ECOG performance status of 0 or 1
- •6. Patients expected to survive over 90 days
- •7. Patients with percutaneous oxygen saturation over 94%, as measured by pulse oximeter at rest, without supplemental O2 within 7 days before enrollment. However, if the baseline measurement is not included within 7 days before the initial dose of the investigational product, it should be reconfirmed that the baseline measurement is met.
- •8. Patients whose latest laboratory values obtained within 7 days of enrollment meet the following criteria. However, if the laboratory test at the time of registration is not included within 7 days before the first administration of the investigational product, it should be reconfirmed that the laboratory test before the first administration of the investigational product meets the following criteria. In all cases, laboratory test values are those for which granulocyte colony-stimulating factor (G-CSF formulation) or blood transfusion was not received within 14 days before the test date. White blood cell count > 2,000/m3 and neutrophil count > 15000/m3 Platelet count > = 100,000/m3 Hb > = 9.0 g/d L AST (GOT) and ALT (GPT) are not more than 3.0 times the upper limit of the facility reference value. Total bilirubin not more than 2.0 times the upper limit of institutional standard value Serum creatinine not more than 1.5 times the upper limit of the reference value at the institution Or creatinine clearance (Cockcroft estimates) > 45 m L/m in.
- •9. Patients who have been fully informed of the details of the study by the investigator or sub investigator using a written informed consent form and who voluntarily agree to participate in the study
排除标准
- •1. Patients with a complication or history of severe hypersensitivity reactions to other drugs including antibody preparations
- •2. Patients with a history of concomitant autoimmune disease or chronic or recurrent autoimmune disease. However, patients with skin disease that does not require systemic therapy (Vitiligo, psoriasis, and alopecia), disease that does not appear to recur in the absence of external triggers, or associated hypothyroidism that can be managed with hormone replacement therapy can be enrolled.
- •3. Patients with multiple cancers (Patients with a history of completely resected basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in situ, carcinoma in mucosa or superficial bladder cancer, or other cancers that have not recurred for more than 5 years can be enrolled)
- •4. Patients with brain or meningeal metastases. However, patients who are asymptomatic and do not require treatment may be enrolled. Patients whose disease is stable after completion of treatment for the lesion at least 28 days prior to entry into the study and who do not require continued use of systemic adrenocortical hormones during the 14 days prior to entry into the study can be enrolled.
- •5. Patients with a complication or history of interstitial lung disease or pulmonary fibrosis diagnosed by diagnostic imaging or clinical findings. For radiation pneumonitis,however, patients with confirmed fibrosis stabilization and no risk of recurrence can be enrolled.
- •6. Patients with coexisting diverticulitis or symptomatic gastrointestinal ulcer disease
- •7. Patients with accumulation of pericardial or ascites requiring drainage more frequently than once every 2 weeks
- •8. Patients with pericardial effusion or ascites requiring drainage more frequently than once every 2 weeks
- •9. Patients with pain associated with uncontrollable tumors
- •10. Patients with a history of transient ischemic attack, cerebrovascular attack, thrombosis, or thromboembolism (Pulmonary embolism or deep vein thrombosis) within 18 days before enrollment
- •11. Patients with the following uncontrolled or significant cardiovascular diseases
- •i.Myocardial infarction within 180 days before enrollment
- •ii.Uncontrolled angina within 180 days before enrollment
- •iii.New York Heart Association (NYHA) class III or IV congestive heart failure
- •iv.Uncontrolled hypertension (Systolic blood pressure of 150 mmHg or more or diastolic blood pressure of 90 mmHg or more lasting for 24 hours or more, etc.) despite appropriate treatment
- •v.uncontrollable arrhythmia
- •12. Patients receiving anticoagulant therapy (Exclude antiplatelet therapy, including low-dose aspirin)
- •(Except in patients who have been controlled with anticoagulation)
- •13. Patients with uncontrolled diabetes
- •14. Patients with systemic infections requiring treatment
- •15. HIV-1 antibody test, HIV-2 antibody test, HTLV-1 antibody test,
- •Patients with positive HBs antigen test or HCV antibody test.
- •Patients with negative HBsAg test but positive HBsAb test or HBcAb test and HBV-DNA quantitation above detection sensitivity
- •16. ONO-4538 (MDX-1106 or BMS-936558),
- •Anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody, anti-CD137 antibody, anti-CTLA-4 antibody, or other antibody therapies intended to control T cells Patients with a history of prior drug therapy
- •17. Surgery with general, local, or surface anesthesia within 14 days before enrollment patient receiving therapy
- •18. Patients who underwent pleural, peritoneal, or pericardial adhesions within 28 day
研究者
相似试验
进行中（未招募）
1 期
ivolumab with chemotherapy in pleural mesothelioma after surgeryMedDRA version: 20.0Level: PTClassification code 10059518Term: Pleural mesothelioma malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Malignant Pleural MesotheliomaEUCTR2019-002466-13-DEInstitut für Klinische Krebsforschung IKF GmbH92
招募中
1 期
Optimising regulatory T cell depletion with cyclophosphamide in combination with chemotherapy for enhanced anti-tumour immunity in patients with non-small cell lung cancer (NSCLC) and malignant mesothelioma (MM).Malignant MesotheliomaNon small cell lung cancerCancer - Lung - MesotheliomaCancer - Lung - Non small cellACTRN12609000260224Sir Charles Gairdner Hospital33
已完成
2 期
Nivolumab with Chemotherapy in Pleural Mesothelioma After SurgeryPleural Mesothelioma MalignantNCT04177953Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest92
已完成
2 期
ivolumab monotherapy in Rare tumor patients with mismatch repair deficiency biomarker: A phase II trialRare cancers with MSI-high or dMMRJPRN-jRCT2091220344Kan Yonemori, National Cancer Center Hospital15
进行中（未招募）
不适用
Treatment of malignant mesothelioma with pemetrexed (Alimta) + platinum (4 courses) or pemetrexed (Alimta) + platinum (4 courses) followed by Caelyx single drug (4 courses). - The Pea-Fowl StudyMalignant pleural mesoteliomaMedDRA version: 9.1Level: LLTClassification code 10027407Term: Mesothelioma malignantEUCTR2007-005398-73-SEKarolinska University Hospital125